Distribution of high and low risk HPV types by cytological status: A population based study from Italy

Infectious Agents and Cancer

Volumn 6, Issue 1, 2011, Pages

  Giorgi Rossi, Paolo ^a   Chini, Francesco ^a   Bisanzi, Simonetta ^b   Burroni, Elena ^b   Carillo, Giuseppe ^c   Lattanzi, Amedeo ^d   Angeloni, Claudio ^d   Scalisi, Aurora ^e   MacIs, Rosalba ^f   Pini, Maria T ^g   Capparucci, Paola ^h   Guasticchi, Gabriella ^a   Carozzi, Francesca M ^b  

^a Agency for Public Health   (Italy)

^b ISPO   (Italy)

^c San Giuseppe Moscati Hospital   (Italy)

^d ASL Teramo   (Italy)

^e ASL Catania   (Italy)

^f Territorial Department of Nephrology and Dialysis   (Italy)

^g Coordinamento Screening ASL Roma C ^*  (Italy)

^h ASL Roma B   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; CYTOLOGY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; ITALY; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VERRUCA VULGARIS; WART VIRUS;

EID: 78651580191     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-6-2     Document Type: Article

References (32)

1. Intesa del 20 dicembre 2007 tra il Ministero della Salute, le Regioni e le Province Autonome di Trento e Bolzano, "Strategia per l'offerta attiva del vaccino contro l'infezione da HPV in Italia".
2. Workshop. La prevenzione dell'infezione da papilloma virus umano in Italia. (Rapporti ISTISAN 10/25) Roma, 28 settembre 2009. C Giambi S De Santis (Ed), Atti. Roma: Istituto Superiore di Sanit 2010
3. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. P Giorgi Rossi S Bisanzi I Paganini A Di Iasi C Angeloni A Scalisi R Macis MT Pini F Chini FM Carozzi HPV prevalence Italian Working Group, BMC Infectious Diseases 2010 10 214 20646310
4. The 2001 Bethesda System: terminology for reporting results of cervical cytology. D Solomon D Davey R Kurman A Moriarty D O'Connor M Prey S Raab M Sherman D Wilbur T Wright Jr N Young (Pubitemid 34437346)
5. Effect of circulation and discussion of cervical smears on agreement between laboratories. G Ronco G Montanari M Confortini F Parisio E Berardengo AM Delpiano S Arnaud D Campione D Baldini P Poll E Lynge E Mancini N Segnan, Cytopathology 2003 14 3 115 20 10.1046/j.1365-2303.2003.00035.x 12828719 (Pubitemid 36819177)
6. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. FM Carozzi A Del Mistro M Confortini C Sani D Puliti R Trevisan L De Marco A Gillio Tos S Girlando PD Palma A Pellegrini ML Schiboni P Crucitti P Pierotti A Vignato G Ronco, Am J Clin Pathol 2005 124 716 21 10.1309/84E5WHJQHK83BGQD 16203283
7. WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. V Cogliano R Baan K Straif Y Grosse B Secretan F El Ghissassi, Lancet Oncol 2005 6 204 10.1016/S1470-2045(05)70086-3 15830458
8. sGP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. AJ Van den Brule R Pol N Fransen-Daalmeijer LM Schouls CJ Meijer PJ Snijders, J Clin Microbiol 2002 40 779 87 10.1128/JCM.40.3.779-787.2002 11880393 (Pubitemid 34208623)
9. Determination of genital human papillomavirus infection using consensus PCR, p. 132-152. HM Bauer CE Greer MM Manos, Diagnostic molecular pathology: a practical approach Oxford University Press, Oxford, United Kingdom, Herrington CS, McGee JOD, 1992
10. The polymerase chain reaction for human papillomavirus screening in diagnostic cytopathology of the cervix. JMM Walboomers PWJ Melkert AJC Van Den Brule PJF Snijders CJLM Meijer, A practical approach Oxford University Press, Oxford, United Kingdom, Herrington CS, McGee JOD, 1992
11. Inference about population attributable risk from cross-sectional studies. JL Fleiss, Am J Epidemiol 1979 110 2 103 4 313702 (Pubitemid 10209693)
12. Modern Epidemiology. KJ Rothman S Greenland TL Lash, Philadelphia: Lippincott Williams and Witkins 3 2008 295 7
13. Stata Statistical Software, Release 8.0 College Station, TX: Stata Corporation
14. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. G Ronco N Segnan P Giorgi-Rossi M Zappa GP Casadei F Carozzi P Dalla Palma A Del Mistro S Folicaldi A Gillio-Tos G Nardo C Naldoni P Schincaglia M Zorzi M Confortini J Cuzick New Technologies for Cervical Cancer Working Group, J Natl Cancer Inst 2006 98 765 74 10.1093/jnci/djj209 16757701 (Pubitemid 43983300)
15. New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. G Ronco P Giorgi-Rossi F Carozzi M Confortini P Dalla Palma A Del Mistro A Gillio-Tos D Minucci C Naldoni R Rizzolo P Schincaglia R Volante M Zappa M Zorzi J Cuzick N Segnan, J Natl Cancer Inst 2008 100 492 501 Epub 2008 Mar 25 10.1093/jnci/djn065 18364502
16. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. C Zhao RM Austin, Cancer 2008 114 4 242 8 10.1002/cncr.23598 18484643
17. Extension of organised cervical cancer screening programmes in Italy and their process indicators: 2007 activity. G Ronco P Giubilato C Naldoni M Zorzi E Anghinoni A Scalisi P Dalla Palma L Zanier A Barca MD Gaimo R Maglietta E Mancini R Pizzuti A Iossa N Segnan M Zappa, Epidemiol Prev 2009 33 3 Suppl 2 41 56 19776486
18. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. GM Clifford S Gallus R Herrero N Mũoz PJ Snijders S Vaccarella PT Anh C Ferreccio NT Hieu E Matos M Molano R Rajkumar G Ronco S de Sanjosé HR Shin S Sukvirach JO Thomas S Tunsakul CJ Meijer S Franceschi IARC HPV Prevalence Surveys Study Group, Lancet 2005 366 9490 991 8 10.1016/S0140-6736(05)67069-9 16168781 (Pubitemid 41323035)
19. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. GM Clifford RK Rana S Franceschi JS Smith G Gough JM Pimenta, Cancer Epidemiol Biomarkers Prev 2005 14 5 1157 6 10.1158/1055-9965.EPI-04-0812 15894666
20. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. GM Clifford JS Smith T Aguado S Franceschi, Br J Cancer 2003 89 1 101 5 10.1038/sj.bjc.6601024 12838308 (Pubitemid 36897943)
21. HPV triage for Low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. G Ronco J Cuzick N Segnan S Brezzi F Carozzi S Folicaldi P Dalla Palma A Del Mistro A Gillio-Tos P Giubilato C Naldoni E Polla A Iossa M Zorzi M Confortini PM Giorgi-Rossi the NTCC Working Group, Eur J Cancer 2007 43 476 480 10.1016/j.ejca.2006.11.013 17223540 (Pubitemid 46177594)
22. HPV vaccination and colposcopy workload of screening programmes. M Zorzi P Giorgi Rossi, Vaccine 2008 26 6743 6744 10.1016/j.vaccine.2008.10.007 18950669
23. Prevalence of HPV types in high grade cervical intraepithelial neoplasia and cancer in Italy. FM Carozzi ML Tornesello E Burroni G Loquercio G Carillo C Angeloni A Scalisi R Macis F Chini FM Buonaguro P Giorgi Rossi the HPV Prevalence Italian Working Group, Cancer Epidemiol Biomarkers Prev 2010 19 9 2389 2400 10.1158/1055-9965.EPI-10-0131 20826836
24. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. J Cuzick A Castãán P Sasieni, Br J Cancer 2010 102 5 933 9 Epub 2010 Jan 26 10.1038/sj.bjc.6605528 20104226
25. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. EL Franco SM Mahmud J Tota A Ferenczy F Coutlée, Arch Med Res 2009 40 6 478 85 Epub 2009 Jul 25 10.1016/j.arcmed.2009.06.003 19853188
26. Cervical cancer screening following prophylactic human papillomavirus vaccination. EL Franco J Cuzick, Vaccine 2008 26 Suppl 1 16 23 10.1016/j.vaccine.2007.11.069 18642468
27. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. G Ronco P Giorgi-Rossi F Carozzi M Confortini P Dalla Palma A Del Mistro B Ghiringhello S Girlando A Gillio-Tos L De Marco C Naldoni P Pierotti R Rizzolo P Schincaglia M Zorzi M Zappa N Segnan J Cuzick New Technologies for Cervical Cancer screening (NTCC) Working Group, Lancet Oncol 2010 11 3 249 57 10.1016/S1470-2045(09)70360-2 20089449
28. Estimation of Pap-test coverage in an area with an organised screening program: challenges for survey methods. P Giorgi Rossi G Esposito S Brezzi A Brachini P Raggi A Federici, BMC Health Serv Res 2006 6 36 10.1186/1472-6963-6- 36 16545125
29. Interaction of spontaneous and organised screening for cervical cancer in Turin, Italy. G Ronco N Segnan L Giordano S Pilutti C Senore A Ponti R Volante, Eur J Cancer 1997 33 1262 7 10.1016/S0959-8049(97)00076-2 9301453 (Pubitemid 27359646)
30. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. L Bruni M Diaz X Castellsagué E Ferrer FX Bosch S de Sanjosé J Infect Dis 2010 202 12 1789 99 10.1086/657321 21067372
31. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. DR Brown SK Kjaer K Sigurdsson OE Iversen M Hernandez-Avila CM Wheeler G Perez LA Koutsky EH Tay P Garcia KA Ault SM Garland S Leodolter SE Olsson GW Tang DG Ferris J Paavonen M Steben FX Bosch J Dillner EA Joura RJ Kurman S Majewski N Mũoz ER Myers LL Villa FJ Taddeo C Roberts A Tadesse J Bryan LC Lupinacci KE Giacoletti HL Sings M James TM Hesley E Barr, J Infect Dis 2009 199 7 926 35 10.1086/597307 19236279
32. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. J Paavonen P Naud J Salmerán CM Wheeler SN Chow D Apter H Kitchener X Castellsague JC Teixeira SR Skinner J Hedrick U Jaisamrarn G Limson S Garland A Szarewski B Romanowski FY Aoki TF Schwarz WA Poppe FX Bosch D Jenkins K Hardt T Zahaf D Descamps F Struyf M Lehtinen G Dubin HPV PATRICIA Study Group M Greenacre, Lancet 2009 374 9686 301 14 Epub 2009 Jul 6. Erratum in: Lancet. 2010; 376(9746): 1054 10.1016/S0140-6736(09)61248-4 19586656